Algeta ASA Receives FDA Approval for Prostate Cancer Drug

by Kathy Jones on  May 16, 2013 at 8:46 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Norwegian pharmaceutical company Algeta ASA announced that it has secured the US Food and Drug Administration approval to market its prostate cancer drug in the country.

The drug, known as Xofigo, can be used to treat prostate cancer in cases where the cancer has spread to the bones.
 Algeta ASA Receives FDA Approval for Prostate Cancer Drug
Algeta ASA Receives FDA Approval for Prostate Cancer Drug

The drug works in treating the castration-resistant prostate cancer by releasing targeted alpha-particle-emitting radiation into the bones which kill the cancer cells but inflict limited damage to the surrounding tissue.

Algeta has joined hands with German drug maker Bayer in marketing the drug to urologists and oncologists in the US. Bayer had filed the new drug application with the FDA and has exclusive marketing rights of the drug outside the US. Analysts predict that Xofigo could generate as much as $1.3 billion in sales annually.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Signature Drug Toxicity Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive